Fabry Disease  >>  Replagal (agalsidase alfa)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
NCT02930655: A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

Completed
1b
14
Europe
Lucerastat, ACT-434964, Enzyme replacement therapy (ERT), Fabrazyme, Replagal
Idorsia Pharmaceuticals Ltd.
Fabry Disease
02/16
02/16

Download Options